PriceTargets.com logo

Mayne Pharma Group - MAYNF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.47 As of 04/19/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for MAYNF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mayne Pharma Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MAYNF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MAYNF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Mayne Pharma Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.47.

This chart shows the closing price for MAYNF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Mayne Pharma Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/21/2021CitigroupDowngradeBuy ➝ Neutral
8/30/2021CitigroupUpgradeNeutral ➝ Buy$7.00
5/17/2019CitigroupDowngradeBuy ➝ Neutral
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Mayne Pharma Group logo
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Read More

Today's Range

Now: $4.47
Low: $4.47
High: $4.47

50 Day Range

MA: $4.25
Low: $3.55
High: $4.59

52 Week Range

Now: $4.47
Low: $1.90
High: $4.59

Volume

N/A

Average Volume

1,442 shs

Market Capitalization

N/A

P/E Ratio

124.17

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mayne Pharma Group?

The following Wall Street research analysts have issued research reports on Mayne Pharma Group in the last twelve months:
View the latest analyst ratings for MAYNF.

What is the current price target for Mayne Pharma Group?

0 Wall Street analysts have set twelve-month price targets for Mayne Pharma Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mayne Pharma Group in the next year.
View the latest price targets for MAYNF.

What is the current consensus analyst rating for Mayne Pharma Group?

Mayne Pharma Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MAYNF.

What other companies compete with Mayne Pharma Group?

Other companies that are similar to Mayne Pharma Group include AstraZeneca, Cosmo Pharmaceuticals, CSPC Pharmaceutical Group, Daiichi Sankyo and Dechra Pharmaceuticals. Learn More about companies similar to Mayne Pharma Group.

How do I contact Mayne Pharma Group's investor relations team?

Mayne Pharma Group's physical mailing address is 1538 Main North Road, Salisbury, South Australia. The company's listed phone number is (188) 209-2666. The official website for Mayne Pharma Group is www.maynepharma.com. Learn More about contacing Mayne Pharma Group investor relations.